Related references
Note: Only part of the references are listed.Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells
Teru Hideshima et al.
BLOOD (2009)
Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1
Masaki Ri et al.
CANCER SCIENCE (2009)
Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells
T. Rueckrich et al.
LEUKEMIA (2009)
Proteasome inhibitors in the treatment of multiple myeloma
J. J. Shah et al.
LEUKEMIA (2009)
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells
Qiuyan Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Many facets of bortezomib resistance/susceptibility
Shaji Kumar et al.
BLOOD (2008)
Molecular basis of bortezomib resistance:: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
Ruud Oerlemans et al.
BLOOD (2008)
Point mutation of the proteasome β5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line
Shuqing Lu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib
D. A. Fennell et al.
ONCOGENE (2008)
Integrated endoplasmic reticulum stress responses in cancer
Michel Moenner et al.
CANCER RESEARCH (2007)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome
M Groll et al.
STRUCTURE (2006)
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
P Perez-Galan et al.
BLOOD (2006)
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis
ST Nawrocki et al.
CANCER RESEARCH (2005)
NFκB:: Linking inflammation and immunity to cancer development and progression
M Karin et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors
HB Zhu et al.
ONCOGENE (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The development of proteasome inhibitors as anticancer drugs
J Adams
CANCER CELL (2004)
Share Paper
